

1/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA

102000021448

Revision Date: 24.04.2023

Print Date: 22.02.2024

## SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier

Trade name LUNA EXPERIENCE SC400

Product code (UVP) 84476838

1.2 Relevant identified uses of the substance or mixture and uses advised against

**Use** Fungicide

1.3 Details of the supplier of the safety data sheet

**Supplier** Bayer (Pty) Ltd.

27 Wrench Road, P.O. Box 143

1600 Isando South Africa

**Telephone** +27 (011) 921 5911 **Telefax** +27 (011) 921 5766

Responsible Department QHSE - Nigel, South Africa

+27 (011) 365 8675 (during business hours only)

1.4 Emergency telephone no.

Emergency telephone no. +27 (0861) 555 777 (Western Cape Poisons Helpline)

**Global Incident Response** 

Hotline (24h)

+1 (760) 476 3964 (Company 3E for Bayer AG, Crop Science Division)

### **SECTION 2: HAZARDS IDENTIFICATION**

#### 2.1 Classification of the substance or mixture

Classification in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

Eye irritation: Category 2

H319 Causes serious eye irritation.

Reproductive toxicity: Category 2

H361d Suspected of damaging the unborn child.

Chronic aquatic toxicity: Category 1

H410 Very toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

Labelling in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

Hazard label for supply/use required.

Hazardous components which must be listed on the label:

Tebuconazole



2/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA

102000021448

Revision Date: 24.04.2023

Print Date: 22.02.2024

### Fluopyram







## Signal word: Warning

### **Hazard statements**

H319 Causes serious eye irritation.

H361d Suspected of damaging the unborn child.
H410 Very toxic to aquatic life with long lasting effects.

EUH208 Contains 1,2-benzisothiazolin-3-one, reaction mass of 5-chloro-2-

methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3- one (3:1). May produce an

allergic reaction.

EUH401 To avoid risks to human health and the environment, comply with the instructions for use.

#### **Precautionary statements**

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor/ physician.
Dispose of contents/container in accordance with local regulation.

#### 2.3 Other hazards

No additional hazards known beside those mentioned.

Tebuconazole: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB). Fluopyram: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).

Ecological information: The substance/mixture does not contain components considered to

have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to

have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS 3.2 Mixtures

#### **Chemical nature**

Suspension concentrate (=flowable concentrate)(SC) Tebuconazole/Fluopyram 200:200 g/l

### **Hazardous components**

Hazard statements according to Regulation (EC) No. 1272/2008

Name	CAS-No. /	Classification	Conc. [%]
	EC-No. /	REGULATION (EC) No	
	REACH Reg. No.	1272/2008	



3/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA
102000021448

Revision Date: 24.04.2023
Print Date: 22.02.2024

Tebuconazole	107534-96-3	Acute Tox. 4, H302 Repr. 2, H361d Aquatic Acute 1, H400 Aquatic Chronic 1, H410	17,70
Fluopyram	658066-35-4 619-797-7	Aquatic Chronic 2, H411	
Alkyl polysaccharide	68515-73-1 01-2119488530-36-XXXX	Eye Dam. 1, H318	> 3,0 - < 10,0
Alcohols, C11-14-iso-, C13-rich, ethoxylated	78330-21-9	Acute Tox. 4, H302 Eye Dam. 1, H318 Aquatic Chronic 3, H412	< 3,0
1,2-Benzisothiazol-3(2H)- one	2634-33-5 01-2120761540-60-xxxx	Acute Tox. 4, H302 Acute Tox. 2, H330 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Acute 1, H400 Aquatic Chronic 2, H411	> 0,0050 - < 0,050
reaction mass of 5-chloro-2- methyl-2H-isothiazol-3-on e and 2-methyl-2H-isothiazol-3- one (3:1)	55965-84-9	Acute Tox. 3, H301 Acute Tox. 2, H310 Acute Tox. 2, H330 Skin Corr. 1C, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410	
1,2-Propanediol	57-55-6 01-2119456809-23-XXXX	Not classified	>= 1,0
Polyethylene-polypropyle ne copolymer	9003-11-6	Not classified	>= 1,0

### **Further information**

1,2-Benzisothiazol-	2634-33-5	M-Factor: 1 (acute)
3(2H)-one		

For the full text of the H-Statements mentioned in this Section, see Section 16.

#### **SECTION 4: FIRST AID MEASURES**

### 4.1 Description of first aid measures

General advice Move out of dangerous area. Place and transport victim in stable

position (lying sideways). Remove contaminated clothing immediately

and dispose of safely.

**Inhalation** Move to fresh air. Keep patient warm and at rest. Call a physician or

poison control center immediately.

**Skin contact** Wash off thoroughly with plenty of soap and water, if available with

polyethyleneglycol 400, subsequently rinse with water. Call a physician

or poison control center immediately.

**Eye contact** Rinse immediately with plenty of water, also under the eyelids, for at

least 15 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing eye. Get medical attention if irritation

develops and persists.



4/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA

102000021448

Revision Date: 24.04.2023
Print Date: 22.02.2024

**Ingestion** Rinse mouth. Do NOT induce vomiting. Call a physician or poison

control center immediately.

4.2 Most important symptoms and effects, both acute and delayed

**Symptoms** No symptoms known or expected.

4.3 Indication of any immediate medical attention and special treatment needed

**Treat symptomatically.** In case of ingestion gastric lavage should be

considered in cases of significant ingestions only within the first 2 hours. However, the application of activated charcoal and sodium sulphate is

always advisable. There is no specific antidote.

**SECTION 5: FIREFIGHTING MEASURES** 

5.1 Extinguishing media

Suitable Water spray, Carbon dioxide (CO2), Alcohol-resistant foam, Sand

**Unsuitable** High volume water jet

5.2 Special hazards arising from the substance or

mixture

In the event of fire the following may be released:, Hydrogen chloride (HCl), Hydrogen cyanide (hydrocyanic acid), Hydrogen fluoride, Carbon monoxide (CO), Carbon dioxide (CO2), Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective

equipment for firefighters

In the event of fire and/or explosion do not breathe fumes. Wear

self-contained breathing apparatus and protective suit.

**Further information** Contain the spread of the fire-fighting media. Do not allow run-off from

fire fighting to enter drains or water courses.

**SECTION 6: ACCIDENTAL RELEASE MEASURES** 

6.1 Personal precautions, protective equipment and emergency procedures

**Precautions** Avoid contact with spilled product or contaminated surfaces. Use

personal protective equipment.

6.2 Environmental

precautions

Do not allow to get into surface water, drains and ground water.

6.3 Methods and materials for containment and cleaning up

**Methods for cleaning up**Soak up with inert absorbent material (e.g. sand, silica gel, acid binder,

universal binder, sawdust). Clean contaminated floors and objects thoroughly, observing environmental regulations. Collect and transfer the product into a properly labelled and tightly closed container.

6.4 Reference to other

sections

Information regarding safe handling, see section 7.

Information regarding personal protective equipment, see section 8.

Information regarding waste disposal, see section 13.

**SECTION 7: HANDLING AND STORAGE** 

7.1 Precautions for safe handling

**Advice on safe handling** Use only in area provided with appropriate exhaust ventilation.



5/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA
102000021448

Revision Date: 24.04.2023
Print Date: 22.02.2024

Hygiene measures Avoid contact with skin, eyes and clothing. Keep working clothes

separately. Wash hands before breaks and immediately after handling the product. Remove soiled clothing immediately and clean thoroughly before using again. Garments that cannot be cleaned must be destroyed

(burnt).

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Store in a place accessible by authorized persons only. Store in original container. Keep containers tightly closed in a dry, cool and well-ventilated

place. Keep away from direct sunlight. Protect from frost.

Advice on common storage Keep av

Keep away from food, drink and animal feedingstuffs.

Suitable materials

HDPE (high density polyethylene)

Coex HDPE/EVOH/HDPE

7.3 Specific end use(s)

Refer to the label and/or leaflet.

#### **SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**

#### 8.1 Control parameters

Components	CAS-No.	Control parameters	Update	Basis
Tebuconazole	107534-96-3	0,2 mg/m3 (SK-ABS)		OES BCS*
Fluopyram	658066-35-4	0,34 mg/m3 (TWA)		OES BCS*

<sup>\*</sup>OES BCS: Internal Bayer AG, Crop Science Division "Occupational Exposure Standard"

#### 8.2 Exposure controls

**Respiratory protection** Respiratory protection is not required under anticipated circumstances

of exposure.

Respiratory protection should only be used to control residual risk of short duration activities, when all reasonably practicable steps have been taken to reduce exposure at source e.g. containment and/or local extract ventilation. Always follow respirator manufacturer's

instructions regarding wearing and maintenance.

**Hand protection** Please observe the instructions regarding permeability and

breakthrough time which are provided by the supplier of the gloves. Also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion, and the

contact time.

Wash gloves when contaminated. Dispose of when contaminated inside, when perforated or when contamination on the outside cannot be removed. Wash hands frequently and always before eating,

drinking, smoking or using the toilet.

Material Nitrile rubber
Rate of permeability > 480 min
Glove thickness > 0,4 mm
Protective index Class 6

Directive Protective gloves complying with EN

374.

**Eye protection** Wear goggles (conforming to EN166, Field of Use = 5 or equivalent).

Skin and body protection Wear standard coveralls and Category 3 Type 6 suit.



6/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA

102000021448

Revision Date: 24.04.2023
Print Date: 22.02.2024

If there is a risk of significant exposure, consider a higher protective

type suit.

Wear two layers of clothing wherever possible. Polyester/cotton or cotton overalls should be worn under chemical protection suit and

should be professionally laundered frequently.

**General protective measures** If product is handled while not enclosed, and if contact may occur:

Complete suit protecting against chemicals

### **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

9.1 Information on basic physical and chemical properties

Form suspension

Colour white to beige

Odour characteristic

Odour Threshold No data available

**pH** 5,0 - 8,0 (100 %) (23 °C)

Melting point/range No data available

**Boiling Point**  $101 \,^{\circ}\text{C}$  **Flash point**  $> 101 \,^{\circ}\text{C}$ 

No flash point - Determination conducted up to the boiling point.

Flammability No data available

Auto-ignition temperature 440 °C

Thermal decomposition No data available

Minimum ignition energyNo data availableSelf-accelaratingNo data available

decomposition temperature

(SADT)

Upper explosion limitNo data availableLower explosion limitNo data availableVapour pressureNo data availableEvaporation rateNo data availableRelative vapour densityNo data availableRelative densityNo data available

**Density** ca. 1,13 g/cm³ (20 °C)

Water solubility completely miscible

Partition coefficient: n-octanol/water

Tebuconazole: log Pow: 3,7

Fluopyram: log Pow: 3,3

Viscosity, dynamicNo data availableViscosity, kinematicNo data available



7/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA

102000021448

Revision Date: 24.04.2023

Print Date: 22.02.2024

Surface tension 28 mN/m (25 °C)

Oxidizing properties No oxidizing properties

**Explosivity** Not explosive

92/69/EEC, A.14 / OECD 113

**9.2 Other information** Further safety related physical-chemical data are not known.

### **SECTION 10: STABILITY AND REACTIVITY**

**10.1 Reactivity** Stable under normal conditions.

**10.2 Chemical stability** Stable under recommended storage conditions.

**10.3 Possibility of**No hazardous reactions when stored and handled according to

**hazardous reactions** prescribed instructions.

**10.4 Conditions to avoid** Extremes of temperature and direct sunlight.

freezing

**10.5 Incompatible materials** Store only in the original container.

10.6 Hazardous

decomposition products

No decomposition products expected under normal conditions of use.

### **SECTION 11: TOXICOLOGICAL INFORMATION**

11.1 Information on hazard classes as defined in regulation (EC) No 1272/2008

Acute oral toxicity LD50 (Rat) > 2.000 mg/kg

Test conducted with a similar formulation.

No deaths

Acute inhalation toxicity LC50 (Rat) > 1,9 mg/l

Exposure time: 4 h

Determined in the form of liquid aerosol. Highest attainable concentration.

No deaths

Test conducted with a similar formulation.

Acute dermal toxicity LD50 (Rat) > 2.000 mg/kg

Test conducted with a similar formulation.

No deaths

**Skin corrosion/irritation** No skin irritation (Rabbit)

Test conducted with a similar formulation.

Serious eye damage/eye

irritation

Irritating to eyes. (Rabbit)

**Respiratory or skin** Skin: Non-sensitizing. (Mouse)

sensitisation OECD Test Guideline 429, local lymph node assay (LLNA)

Test conducted with a similar formulation.



8/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA Revision Date: 24.04.2023 102000021448 Print Date: 22.02.2024

### Assessment STOT Specific target organ toxicity - single exposure

Tebuconazole: Based on available data, the classification criteria are not met. Fluopyram: Based on available data, the classification criteria are not met.

#### Assessment STOT Specific target organ toxicity - repeated exposure

Tebuconazole did not cause specific target organ toxicity in experimental animal studies. Fluopyram did not cause specific target organ toxicity in experimental animal studies.

#### **Assessment mutagenicity**

Tebuconazole was not mutagenic or genotoxic in a battery of in vitro and in vivo tests. Fluopyram was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

#### Assessment carcinogenicity

Tebuconazole caused at high dose levels an increased incidence of tumours in mice in the following organ(s): Liver. The mechanism of tumour formation is not considered to be relevant to man. Fluopyram caused at high dose levels an increased incidence of tumours in rats in the following organ(s): Liver.

Fluopyram caused at high dose levels an increased incidence of tumours in mice in the following organ(s): Thyroid.

The tumours seen with Fluopyram were caused through a non-genotoxic mechanism, which is not relevant at low doses. The mechanism that triggers these tumours is not relevant to humans.

#### Assessment toxicity to reproduction

Tebuconazole caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Tebuconazole is related to parental toxicity. Fluopyram caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Fluopyram is related to parental toxicity.

#### Assessment developmental toxicity

Tebuconazole caused developmental toxicity only at dose levels toxic to the dams. Tebuconazole caused an increased incidence of post implantation losses, an increased incidence of non-specific malformations. Fluopyram caused developmental toxicity only at dose levels toxic to the dams. The developmental effects seen with Fluopyram are related to maternal toxicity.

#### **Aspiration hazard**

Based on available data, the classification criteria are not met.

#### 11.2 Information on other hazards

### **Endocrine disrupting properties**

Assessment The substance/mixture does not contain components considered to have

endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

### **SECTION 12: ECOLOGICAL INFORMATION**

12.1 Toxicity

**Toxicity to fish** LC50 (Oncorhynchus mykiss (rainbow trout)) 21,7 mg/l

static test; Exposure time: 96 h

Test conducted with a similar formulation.

**Toxicity to aquatic** EC50 (Daphnia magna (Water flea)) 56,9 mg/l



9/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA

102000021448

Revision Date: 24.04.2023
Print Date: 22.02.2024

**invertebrates** Exposure time: 48 h

Test conducted with a similar formulation.

Chronic toxicity to aquatic

invertebrates

NOEC (Daphnia (water flea)): 0,01 mg/l

Exposure time: 21 d

The value mentioned relates to the active ingredient tebuconazole.

**Toxicity to aquatic plants** EC50 (Raphidocelis subcapitata (freshwater green alga)) 17,7 mg/l

Growth rate; Exposure time: 72 h

Test conducted with a similar formulation.

EC50 (Lemna gibba (gibbous duckweed)) 0,237 mg/l

Growth rate; Exposure time: 7 d

The value mentioned relates to the active ingredient tebuconazole.

12.2 Persistence and degradability

**Biodegradability** Tebuconazole:

Not rapidly biodegradable

Fluopyram:

Not rapidly biodegradable

**Koc** Tebuconazole: Koc: 769

Fluopyram: Koc: 279

12.3 Bioaccumulative potential

**Bioaccumulation** Tebuconazole: Bioconcentration factor (BCF) 35 - 59

Does not bioaccumulate.

Fluopyram: Bioconcentration factor (BCF) 18

Does not bioaccumulate.

12.4 Mobility in soil

Mobility in soil Tebuconazole: Slightly mobile in soils

Fluopyram: Moderately mobile in soils

12.5 Results of PBT and vPvB assessment

PBT and vPvB assessment Tebuconazole: This substance is not considered to be persistent,

bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

Fluopyram: This substance is not considered to be persistent,

bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

12.6 Endocrine disrupting properties

Assessment The substance/mixture does not contain components considered to have

endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

Additional ecological

information

No other effects to be mentioned.

#### **SECTION 13: DISPOSAL CONSIDERATIONS**

#### 13.1 Waste treatment methods



10/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA

102000021448

Revision Date: 24.04.2023

Print Date: 22.02.2024

**Product** In accordance with current regulations and, if necessary, after

consultation with the site operator and/or with the responsible authority, the product may be taken to a waste disposal site or incineration plant.

**Contaminated packaging** Triple rinse containers.

Do not re-use empty containers.

Not completely emptied packagings should be disposed of as hazardous

waste.

#### **SECTION 14: TRANSPORT INFORMATION**

**SANS 10231** 

14.1 UN number 3082

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(TEBUCONAZOLE SOLUTION)

14.3 Transport hazard class(es)
14.4 Packaging Group
14.5 Environm. Hazardous Mark
YES

**IMDG** 

14.1 UN number **3082** 

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(TEBUCONAZOLE SOLUTION)

14.3 Transport hazard class(es)14.4 Packaging Group14.5 Marine pollutantYES

**IATA** 

14.1 UN number **3082** 

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(TEBUCONAZOLE SOLUTION)

14.3 Transport hazard class(es) 9
14.4 Packaging Group III
14.5 Environm. Hazardous Mark YES

### 14.6 Special precautions for user

See sections 6 to 8 of this Safety Data Sheet.

### 14.7 Transport in bulk according to IMO instruments

No transport in bulk according to the IBC Code.

#### **SECTION 15: REGULATORY INFORMATION**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture Further information

WHO-classification: U (Unlikely to present acute hazard in normal use)



11/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA
102000021448

Revision Date: 24.04.2023
Print Date: 22.02.2024

### **SECTION 16: OTHER INFORMATION**

#### Text of the hazard statements mentioned in Section 3

H301 Toxic if swallowed.
H302 Harmful if swallowed.
H310 Fatal in contact with skin.

H314 Causes severe skin burns and eye damage.

H315 Causes skin irritation.

H317 May cause an allergic skin reaction. H318 Causes serious eye damage.

H330 Fatal if inhaled.

H361d Suspected of damaging the unborn child.

H400 Very toxic to aquatic life.

H410 Very toxic to aquatic life with long lasting effects.
 H411 Toxic to aquatic life with long lasting effects.
 H412 Harmful to aquatic life with long lasting effects.

### Abbreviations and acronyms

ADN European Agreement concerning the International Carriage of Dangerous Goods by

Inland Waterways

ADR European Agreement concerning the International Carriage of Dangerous Goods by

Road

ATE Acute toxicity estimate

CAS-Nr. Chemical Abstracts Service number

Conc. Concentration

EC-No. European community number ECx Effective concentration to x %

EINECS European inventory of existing commercial substances

ELINCS European list of notified chemical substances

EN European Standard EU European Union

IATA International Air Transport Association

IBC International Code for the Construction and Equipment of Ships Carrying Dangerous

Chemicals in Bulk (IBC Code)

ICx Inhibition concentration to x %

IMDG International Maritime Dangerous Goods

LCx Lethal concentration to x %

LDx Lethal dose to x %

LOEC/LOEL Lowest observed effect concentration/level

MARPOL: International Convention for the prevention of marine pollution from ships

N.O.S. Not otherwise specified

NOEC/NOEL No observed effect concentration/level

OECD Organization for Economic Co-operation and Development

RID Regulations concerning the International Carriage of Dangerous Goods by Rail

TWA Time weighted average

UN United Nations

WHO World health organisation

The information contained within this Safety Data Sheet is in accordance with the guidelines established by Regulation (EU) 1907/2006 and Regulation (EU) 2020/878 amending Regulation (EU) No 1907/2006 and any subsequent amendments. This data sheet complements the user's instructions, but does not replace them. The information it contains is based on the knowledge available about the product concerned at the time it was compiled. Users are further reminded of the possible risks of using a product for purposes other



12/12

### **LUNA EXPERIENCE SC400**

Version 4 / ZA
102000021448

Revision Date: 24.04.2023
Print Date: 22.02.2024

than those for which it was intended. The required information complies with current EEC legislation. Addressees are requested to observe any additional national requirements.

**Reason for Revision:** The following sections have been revised: Section 3: Composition /

Information on Ingredients. Section 8: Exposure Controls / Personal

Protection.

Changes since the last version are highlighted in the margin. This version replaces all previous versions.